Selank
A synthetic heptapeptide analogue of tuftsin — registered in Russia as a pharmaceutical drug for anxiety since 2009. Modulates GABA, upregulates BDNF, and produces anxiolytic effects comparable to benzodiazepines without sedation, tolerance, or dependence risk. The most clinically documented anxiolytic peptide in Russian pharmacology.
What Is Selank?
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a stabilised analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from human immunoglobulin G. A three-amino-acid tail — Pro-Gly-Pro — was added by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences specifically to protect the molecule from rapid enzymatic degradation, giving it a significantly longer half-life than native tuftsin.
Tuftsin itself is produced by the spleen and has known immunomodulatory roles. Selank inherits these properties while exhibiting additional central nervous system activity not seen in native tuftsin. The combination of peripheral immune modulation and central anxiolytic/nootropic effects makes Selank uniquely positioned among peptide research compounds.
In Russia, Selank is marketed under the brand name Selanc as a registered pharmaceutical drug — a 0.15% intranasal solution. It was approved by the Russian Pharmacological Committee in 2009 for the treatment of generalised anxiety disorder and asthenic conditions (neurasthenia). This approval makes Selank one of a very small number of peptide-class drugs that have cleared a national drug regulatory body anywhere in the world.
Selank emerged from the same Soviet-era neuropharmacology research programme that produced Semax (an ACTH analogue) and Cerebrolysin. Russian interest in peptide-based CNS drugs intensified in the 1980s as alternatives to benzodiazepines were sought — compounds that could reduce anxiety without the sedation, cognitive impairment, and addiction liability of classical tranquilisers.
Mechanism of Action
Selank's anxiolytic effects operate through at least three distinct pathways. Understanding each is important for predicting how it will stack, when to use it, and what to expect clinically.
1. GABAergic Modulation
Selank potentiates GABAergic neurotransmission — the same system targeted by benzodiazepines, barbiturates, and alcohol. However, unlike benzodiazepines, Selank does not appear to act directly on GABA-A receptor benzodiazepine binding sites. Instead, it modulates GABA release and uptake through an indirect mechanism that researchers have not fully characterised. The critical difference in practice: benzodiazepines cause receptor downregulation and tolerance with chronic use; Selank does not appear to do this, at least in the clinical timescales studied (14–28 day courses). No withdrawal syndrome has been reported in clinical or animal studies.
2. BDNF Upregulation
Selank consistently upregulates Brain-Derived Neurotrophic Factor (BDNF) expression in the hippocampus. BDNF is central to neuroplasticity, long-term potentiation (LTP), and memory consolidation. This mechanism is shared with Semax, which explains why the two peptides are so commonly paired — Semax prioritises cognitive activation and BDNF production, Selank adds anxiolytic and GABA-modulating effects. Together they address both the drive and the calm required for optimal cognitive performance.
Reduced hippocampal BDNF is strongly associated with treatment-resistant depression, anxiety disorders, and cognitive decline. Selank's BDNF-upregulating effect may explain the antidepressant-adjacent effects some users report, and why Russian clinicians have used it for asthenic and depressive-spectrum conditions beyond pure anxiety.
3. Serotonergic and Enkephalinergic Effects
Selank has mild modulatory effects on serotonin metabolism, increasing serotonin turnover without the direct receptor agonism or reuptake inhibition seen in pharmaceutical antidepressants. It also influences enkephalin metabolism — enkephalins are endogenous opioid peptides involved in stress response regulation. This triple mechanism (GABA + BDNF + serotonin/enkephalin) gives Selank a broader anxiolytic-nootropic profile than single-mechanism compounds, and may account for reports of mood stabilisation distinct from its anti-anxiety effects.
4. Immunomodulation (Tuftsin Backbone)
Via its tuftsin-derived sequence, Selank also modulates innate immune function — specifically influencing natural killer (NK) cell activity and cytokine balance. This is considered a secondary effect for most users, but it may contribute to the general "well-being" quality reported in Russian clinical observations, and distinguishes Selank from purely CNS-targeted anxiolytics.
Evidence Overview & Tiers
Multiple Russian controlled trials (N=62–120) show anxiolytic efficacy vs. benzodiazepines. Limitation: all originate from Russian institutions.
BDNF upregulation confirmed in animal and some clinical data. Memory and attention improvements reported. No large Western RCTs.
Small trials show mood stabilisation in anxiety-adjacent depression. Mechanism plausible (BDNF + serotonin). Not studied as standalone antidepressant.
No large independent Western RCTs. All primary human evidence is from Russia. This is the key limitation of the evidence base.
Selank's overall evidence grade is Emerging (B+) for its primary anxiolytic indication. This is higher than most research peptides because it has legitimate controlled clinical trial data — just not the Western-independent replication that would elevate it to a stronger evidence tier.
The key studies to know: Zozulia et al. (2001) established the anxiolytic mechanism and efficacy versus placebo in generalised anxiety disorder. Semenova et al. (2010) demonstrated BDNF-mediated anxiolytic effects across multiple animal stress models with mechanistic depth. Narkevich et al. (2008) showed hippocampal BDNF upregulation as a core mechanism. Korobov et al. demonstrated superiority to placebo in asthenic disorder with favourable tolerability.
All published Selank human trials originate from Russian institutions. This is not unique — much early Soviet pharmacology never got Western replication. But it does mean we cannot fully rule out publication bias or regulatory-motivated framing. The mechanistic evidence (GABA, BDNF, animal models) is solid. The clinical translation is plausible. But until an independent Western Phase II trial is completed, Selank stays in the Emerging tier.
Primary Uses & Applications
- Generalised Anxiety Disorder — Primary approved indication in Russia. Multiple trials support anxiolytic efficacy comparable to low-dose benzodiazepines without sedation or dependence.
- Cognitive Enhancement — BDNF upregulation, improved attention, working memory, and information processing speed. Commonly stacked with Semax for this purpose.
- Stress Resilience — Reduces cortisol-mediated stress response, modulates enkephalin system. Often used during high-pressure periods (exams, intense work sprints, emotional stress).
- Asthenic Conditions / Neurasthenia — Second approved indication in Russia. Fatigue states characterised by exhaustion, anxiety, and cognitive fog respond well in clinical observations.
- Nootropic Stacking — Combined with Semax as the classic Russian cognitive peptide pair. Semax activates, Selank calms. Together they produce a sharp-but-settled cognitive state.
- Sleep Quality — Some users report improved sleep architecture, likely secondary to reduced evening anxiety rather than direct hypnotic effect. Not studied specifically for sleep.
Protocols & Dosing
Selank is almost exclusively administered intranasally. SubQ injection is pharmacologically viable but intranasal is the standard — it is the route used in all Russian clinical trials and the formulation approved as Selanc. Intranasal administration bypasses first-pass metabolism and allows direct transport via olfactory pathways into the CNS.
Standard Preparation
| Parameter | Standard | Notes |
|---|---|---|
| Vial size | 5 mg | Common research peptide vial |
| Reconstitution | 2 mL bacteriostatic water | Yields 2,500 mcg/mL (2.5 mg/mL) |
| Nasal drop concentration | 300–500 mcg/mL preferred | Dilute further for intranasal: 1 mL peptide solution + 4 mL saline = ~500 mcg/mL. Russian commercial = 0.15% = 1,500 mcg/mL. |
| Per drop volume | ~30–50 µL | Standard nasal dropper. 2–3 drops per nostril = ~120–300 µL per administration. |
| Storage | Refrigerate (2–8°C) | Reconstituted: use within 4–6 weeks. Keep away from light. |
Dosing by Goal
| Goal | Dose per Session | Frequency | Duration |
|---|---|---|---|
| Anxiety / GAD | 400–750 mcg | 2–3× daily | 14–28 days |
| Cognitive enhancement | 250–500 mcg | 1–2× daily (AM + afternoon) | 10–14 days |
| Stress resilience (acute) | 250–500 mcg | Once daily or as needed | 5–10 days |
| Combined nootropic stack | 250–500 mcg | 1× daily (PM, paired with AM Semax) | 10–14 day cycles |
The Russian clinical dose (400–900 mcg/day intranasally) is lower than some online protocols suggest. Higher doses (2,000–3,000 mcg/day) are sometimes referenced in community discussions but lack clinical backing. Start low (250 mcg/session), assess response, and escalate only if needed. More is not more with anxiolytics.
Cycling Protocol
Selank is typically run in defined cycles rather than continuously. No dependence or withdrawal has been documented, but cycling respects the principle of allowing receptor sensitivity to reset and avoids unknown long-term effects.
Days 1–14: Selank Course
250–750 mcg intranasal, 1–3× daily. Optimal window for anxiolytic and BDNF-mediated effects. Most clinical trials used this duration.
Days 15–24: Off Period
10-day washout. Allow neurochemistry to reset. Note and assess any residual effects. During rest, many users transition to Semax (see stacking protocol below).
Days 25+: Next Cycle
Repeat Selank cycle, or begin Semax phase. Many users run 2–3 Selank cycles per year for ongoing anxiety management without tolerance development.
Stacking with Semax
Selank and Semax are the most established peptide pair in the Russian nootropic tradition — complementary in mechanism and timing. Semax is an ACTH(4–7) analogue that drives BDNF production, activates dopaminergic and serotonergic pathways, and produces a pronounced cognitive activation effect. Selank provides GABA modulation, anti-anxiety activity, and its own BDNF contribution. Together they cover the full range of cognitive-wellness targets: activation, focus, anxiety control, and neuroprotection.
Protocol Option A: Daily Split (Advanced)
Best for users managing both anxiety and cognitive performance simultaneously:
- Morning: Semax 100–300 mcg intranasal → cognitive activation, BDNF drive, morning alertness
- Evening: Selank 250–500 mcg intranasal → anxiety reduction, GABA modulation, improved sleep onset
Both are used concurrently. Run 10–14 days on, 10 days off. Not recommended as a first protocol — start with Selank alone first.
Protocol Option B: Sequential Cycling (Standard)
Better for beginners and for separating the effects of each peptide:
Selank Phase
250–500 mcg intranasal 1–2× daily. Establish baseline anxiolytic effect and observe response.
Rest / Washout
10-day off period. No peptides. Note mood, anxiety, and cognition baselines.
Semax Phase
100–300 mcg intranasal 1–2× daily. Cognitive activation, BDNF drive. Contrast with Selank effects from previous cycle.
Evaluate & Decide
Based on response, choose: repeat individually, move to daily split protocol, or take extended break.
Safety Profile
Selank's safety profile is one of its most important advantages over classical anxiolytics. Russian clinical experience across 20+ years of pharmacological use as a registered drug provides more safety data than almost any other research peptide.
Reported Side Effects
At standard doses, Selank is considered well-tolerated. The most commonly reported effects in clinical literature are:
- Mild nasal irritation with intranasal administration (transient)
- Mild initial sedation at higher doses (not typical at standard doses)
- Rare: headache or mild dizziness on first use
No serious adverse events have been reported in published trials at standard doses. No cases of dependence, abuse, or withdrawal syndrome have been documented in the clinical literature.
Who Should Exercise Caution
- Individuals on psychiatric medications — Selank affects GABA and serotonin systems. Those on SSRIs, benzodiazepines, antipsychotics, or MAOIs should consult a psychiatrist before use. Interactions are poorly characterised.
- Pregnancy and lactation — No safety data. Avoid.
- Autoimmune conditions — The tuftsin-derived immunomodulatory activity is a theoretical concern in autoimmune states. No documented adverse cases, but caution applies.
- Children and adolescents — Not studied. Avoid.
In head-to-head Russian clinical comparisons, Selank matched benzodiazepine anxiolytic efficacy with zero reports of sedation, tolerance, or withdrawal — the three defining problems of benzodiazepine therapy. This comparison is what drove Russian regulatory approval and continues to be the strongest safety argument in Selank's evidence base.
Regulatory Status
| Region | Status | Detail |
|---|---|---|
| Russia | Approved Pharmaceutical | Registered drug since 2009. Available as Selanc 0.15% nasal drops. Approved for GAD and neurasthenia. Manufactured by Peptogen. |
| United States | Research Peptide (Gray Area) | Not FDA approved. Not a controlled substance. Cannot legally be sold for human use. Personal importation is not explicitly criminalized but exists in a regulatory gray zone. |
| European Union | Not Approved | No EMA approval. No EU member-state approval. Generally classified as a research compound. Status varies by country. |
| Canada / Australia | Not Approved | Research peptide status. Not scheduled. Importation for personal use exists in gray zone. |
Research Citations
Calculate Your Selank Dose
Use the reconstitution calculator to work out your exact dilution, drop volume, and dosing schedule.